Copyright © 2007 Elsevier Ltd All rights reserved.
Minor groove binder antibody conjugates employing a water soluble β-glucuronide linker
Received 21 December 2006;
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Abstract
The minor groove binder β-glucuronide drug-linker 3 was constructed from amino CBI 1 and determined to be a substrate for Escherichia coli β-glucuronidase (EC 3.2.1.31), resulting in facile drug release. Compound 3 was conjugated to mAbs cAC10 (anti-CD30) and h1F6 (anti-CD70) to give antibody-drug conjugates (ADCs) with potencies comparable to that of free drug 1. The ADCs were largely monomeric at intermediate loading levels (4–5 drug/mAb), in contrast to highly aggregated p-aminobenzylcarbamate dipeptide-based ADCs of 1 previously reported. Significant levels of immunologic specificity were observed with cAC10-3 by comparing antigen positive versus negative cell lines and binding versus non-binding control ADCs. The water soluble β-glucuronide linker is stable in plasma and effectively delivers drugs to target cells leading to potent cytotoxic activities.
Keywords: Aggregation; Antibody; Anti-CD30; Anti-CD70; β-Glucuronidase; β-Glucuronide; cAC10; Cancer; Conjugate; Delivery; Drug; Drug-linker; Minor groove binder; h1F6; Linker; Monoclonal; Release; Targeted






E-mail Article
Add to my Quick Links

Cited By in Scopus (0)






